Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027), covering 2021-12-30 to 2022-09-30. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma [Phase 3]